Best Approaches for Managing Inflammatory Airway Diseases

Best Approaches for Managing Inflammatory Airway Diseases: An Evidence-Based Guide for Physicians

June 30, 2025

Introduction: The Growing Burden of Inflammatory Airway Diseases

Inflammatory airway diseases (IADs)—including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic bronchitis—affect over 500 million people worldwide (Global Burden of Disease Study, 2023). Despite treatment advances, 40% of patients remain poorly controlled, leading to increased hospitalizations and healthcare costs.

For physicians, staying updated on precision diagnostics, emerging biologics, and digital health tools is critical to improving outcomes. This comprehensive, evidence-based guide covers the latest strategies for diagnosis, treatment, and long-term management of IADs in 2024.

Understanding the Basics: What Are Inflammatory Airway Diseases?

Inflammatory airway diseases (IADS) are characterized by chronic airway inflammation, resulting in symptoms such as wheezing, cough, dyspnea or shortness of breath, and chest tightness. Asthma typically presents with reversible airway obstruction and is often driven by allergy or hypersensitivity mechanisms. In contrast, COPD is marked by progressive, irreversible airflow limitation, most commonly associated with smoking or chronic environmental exposures.

Key features and primary triggers of inflammatory airway diseases:

Condition	Key Features	Primary Triggers
Asthma	Reversible Obstruction, Eosinophilic Inflammation	Allergens, Infections, Exercise, Cold air
COPD	Irreversible Airflow Limitation, Neutrophilic Inflammation	Smoking, Pollution
Bronchiectasis	Chronic Mucus Retention, Recurrent Infections	Postinfection, Autoimmune Diseases, Genetic Disorders like Cystic Fibrosis

Despite their distinct clinical and pathophysiological features, many patients may present with symptoms from more than one condition, requiring a dual-pathway or combined therapeutic approach.

Phenotype-Driven Diagnosis: Beyond Spirometry

Phenotype-driven diagnosis goes beyond traditional spirometry by identifying distinct clinical and biological characteristics in patients, allowing for more personalized and effective treatment of respiratory diseases.

Essential Diagnostic Tools for IADs

Test	Best For	Key Findings
FeNO (≥25 ppb)	Eosinophilic Asthma	Predicts Steroid Response
Blood Eosinophils (≥150 cells/μL)	Type 2 Inflammation	Guides Biologic Therapy
HRCT Chest	Bronchiectasis, Emphysema	Detects Structural Damage
Sputum Culture	Chronic Pseudomonas/NTM Infections	Directs Antibiotic Therapy

Helpful Tip: A FeNO level greater than 50 ppb indicates a 90% likelihood of steroid-responsive asthma. In COPD patients, blood eosinophil counts of 300/μL or higher suggest a positive response to inhaled corticosteroids (ICS).

Pharmacotherapy Updates: 2024 Guideline

Here are the 2024 pharmacotherapy updates for physicians:

For asthma, mild cases can be treated with as-needed ICS-formoterol, based on recent research. Moderate to severe asthma is best managed with triple therapy, combining an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). For severe type 2 asthma, biologic treatments or anti-IgE can reduce flare-ups by more than 50%.

In COPD treatment, the first choice is a combination of LAMA and LABA. Inhaled corticosteroids (ICS) should be added if blood eosinophil counts are 300/μL or higher, or if the patient has frequent flare-ups. For those with chronic bronchitis, roflumilast may be helpful.

For bronchiectasis, macrolide antibiotics such as azithromycin help lower the number of flare-ups. Nebulized antibiotics like colistin or tobramycin are used to treat infections caused by Pseudomonas bacteria. Mucolytics like hypertonic saline can help clear mucus from the airways.

When Should You Think About Using Biologics?

If your patient has two or more flare-ups a year despite being on high-dose ICS/LABA (GINA 2024 Update_See Section 5: Severe Asthma Management)
If they show signs of Type 2 inflammation, like a FeNO level of 25 or higher or eosinophils above 150
If they have allergic asthma with IgE levels over 30 IU/mL

Helpful tip:
Tezepelumab has been shown to reduce exacerbations even in patients with non-Type 2 asthma, according to the PATHWAY trial—so it might be worth considering in those cases.

Nonpharmacologic Interventions

Proven Adjunct Therapies

Pulmonary Rehabilitation reduces dyspnea in COPD patients.
Airway clearance devices help decrease infections in bronchiectasis.
For smoking cessation, varenicline combined with counseling has the highest success rate.

Helpful tip:

Digital inhaler sensors improve medication adherence by 58%,

Managing Treatment-Resistant Respiratory Cases: A Step-by-Step Approach

Effectively managing treatment-resistant respiratory conditions such as asthma and COPD requires a systematic approach.

Start by confirming the diagnosis and ruling out common mimics like vocal cord dysfunction (VCD), gastroesophageal reflux disease (GERD), and cardiac conditions.

Next, optimize medication delivery by assessing and improving inhaler techniques, which can be easily monitored using video apps for better patient compliance. It’s important to evaluate and manage comorbidities, especially obstructive sleep apnea (OSA), as it can significantly worsen asthma and COPD control.

If symptoms persist without improvement after 4 to 6 months, consider switching biologic therapies to find a more effective treatment option.

Helpful tip:

Patients experiencing frequent pneumonias should be screened for underlying immunodeficiency, including IgG subclass deficiencies, to address potential causes of recurrent infections.

Breakthrough Therapies in the 2024-2025 Pipeline

The treatment landscape for inflammatory airway diseases is advancing quickly, with several exciting innovations on the horizon:

1. IL-33 Inhibitors (Itepekimab) – A Potential Breakthrough for COPD

Target: The IL-33/ST2 pathway, a key driver of neutrophilic inflammation in COPD
Timeline: Phase III trials are ongoing, with potential approval expected by 2025.

2. Gene Therapy for Alpha-1 Antitrypsin Deficiency

Approach: CRISPR-based liver-directed gene editing offers a breakthrough way to correct the genetic defect causing the disease.

3. AI-Powered Exacerbation Prediction (Google DeepMind & NHS Collaboration)

Technology: Combines electronic health record (EHR) data with wearable device metrics like oxygen saturation and cough frequency
Performance: Predicts exacerbations around 7 days before any symptoms appeared
Impact: A pilot study showed a 33% reduction in COPD hospitalizations, with a planned NHS rollout in 2025.

These advances promise to improve patient outcomes significantly by targeting disease mechanisms more precisely and enabling proactive management.

A Multidisciplinary Approach for Better Outcomes

A collaborative, multidisciplinary approach helps close gaps in care, reduce hospitalizations, and tailor treatments to each patient’s unique phenotype. This ensures patients receive precise, personalized medicine instead of fragmented care. By bringing together experts from different fields, these teams can effectively manage symptoms in the short term while working toward long-term disease control—ultimately improving the quality of life for those with chronic respiratory conditions.

Stay tuned for more insights from our Snot Force Team! At Snot Force Alliance, we actively engage in research collaborations and other initiative to keep advancing our field. Don’t miss out, register now for our upcoming 2025 annual meeting!

< Older Post

Newer Post >

Rural and Underserved Access to Multidisciplinary Airway Expertise

September 22, 2026

Inflammatory airway diseases can impact a patient's quality of life. Untreated conditions leave patients struggling to breathe, coughing regularly, and feeling unwell for months at a time. Airway disease management has undergone significant changes in recent years. Treating airway diseases has become increasingly complex, despite improvements in methodologies and technologies. In rural and underserved regions, many patients lack access to specialty care. Key Takeaways: Providing high-quality care to patients with airway disease requires collaboration across specialties. It is important to expand rural ENT access and access to multidisciplinary clinics. Clinicians in rural communities can improve patient outcomes through collaborations and with creative solutions that expand airway care. The Need for Multidisciplinary Airway Care Airway diseases affect multiple systems of the body and thus are treated by different types of physicians. Allergists, primary care doctors, pulmonologists, and ENT physicians all play a role in caring for patients with airway conditions. Physicians who can facilitate multidisciplinary care can improve diagnostic accuracy while also helping to ensure better patient outcomes. Challenges in Rural and Underserved Communities Rural ENT access is spotty at best. Many rural areas lack specialty physicians and often, patients must travel long distances to tertiary medical centers where they receive care. As a result, patients with limited transportation options may experience delays in diagnosis and care. Sometimes, these specialty care disparities can leave primary care providers to manage complex airway conditions on their own. In areas where insurance coverage is limited, and referral networks are fragmented, patients may struggle with their conditions without treatment at all. The Consequences of These Limitations Delays in diagnosis and treatment mean poor management of chronic conditions and increased reliance on treatment from acute care settings. Under this system, patients become frustrated as they lean on ineffective treatment methods. Methods for Expanding Access There are many methods for expanding access to patients in rural and underserved areas. Telehealth Airway Care The use of telehealth treatment has significantly expanded in recent years. With telehealth tools, hybrid care models combine in-person and virtual visits. This same technology also connects doctors, bringing together specialists and community clinicians. Regional Centers of Excellence Multidisciplinary airway centers have proven effective for helping patients access specialty care. Airway centers make it easier to streamline referrals in complex cases. These airway centers can serve larger geographic areas by setting up outreach clinics in surrounding communities. Collaborative Networks Partnerships and collaborations between physicians are key to ensuring that primary care providers in underserved areas have access to resources and information. Supporting Rural Physicians There are many ways to support rural physicians. Snot Force has committed to build networks for physicians, helping to ensure the dissemination of information across specialties and practice settings. We facilitate collaboration between disciplines to promote innovation in care for underserved communities. We're bringing doctors together to break down specialty care disparities and improve rural ENT access and information. Our research collaborative depends on many medical professionals to participate, and we're always looking for more physicians to join the force. To learn more, contact Snot Force today .